Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Antipsychotic Discontinuation in Alzheimer's Disease
Authors not listed
New York State Psychiatric Institute · 2004
Abstract
In patients with Alzheimer's disease (AD) who respond to antipsychotic treatment of psychosis and/or agitation/aggression, the relapse risk after discontinuation is not established. AD patients with psychosis and/or agitation/aggression receive 16 weeks of open risperidone treatment (Phase A). Responders are then randomized, double-blind, to one of three arms in Phase B: (1) continuation risperidone for 32 weeks, (2) risperidone for 16 weeks followed by placebo for 16 weeks, (3) placebo for 32 weeks. The primary outcome is time to relapse of psychosis/agitation.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2004). Antipsychotic Discontinuation in Alzheimer's Disease. <em>New York State Psychiatric Institute</em>. https://clinicaltrials.gov/study/NCT00417482
Vancouver
Anonymous. Antipsychotic Discontinuation in Alzheimer's Disease. New York State Psychiatric Institute. 2004.
BibTeX
@misc{anon2004Antips,
title = {Antipsychotic Discontinuation in Alzheimer's Disease},
author = {Anonymous},
journal = {New York State Psychiatric Institute},
year = {2004},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of Cincinnati 2011
Open access · US-GOV
A Phase II Window Study of Front-line Axitinib Followed by Axitinib and Radiation for Elderly Patients With Glioblastoma Multiforme (GBM)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company 2022
Open access · US-GOV
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Relapse Prevention Study to Evaluate the Safety and Efficacy of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. 2000
Open access · US-GOV
Efficacy And Safety Of A Flexible Dose Of Risperidone Versus Placebo In The Treatment Of Psychosis Of Alzheimer's Disease.
Nature Cell Co. Ltd. 2023
Open access · US-GOV
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of AstroStem, Autologous Adipose Tissue Derived Mesenchymal Stem Cells, in Patients With Alzheimer's Disease
Otsuka Pharmaceutical Development & Commercialization, Inc. 2000
Open access · US-GOV
A Multicenter, Randomized, Double-Blind, Placebo Controlled Flexible Dose Study of Aripiprazole in the Treatment of Patients With Psychosis Associated With Dementia of Alzheimer's Type
Shanghai Mental Health Center 2017
Open access · US-GOV